Home Newsfeeds Piper Sandler Maintains Overweight on Olin, Lowers Price Target to $68

Piper Sandler Maintains Overweight on Olin, Lowers Price Target to $68

Piper Sandler analyst Charles Neivert maintains Olin (NYSE:OLN) with a Overweight and lowers the price target from $73 to $68.

byBenzinga Newsdesk

September 21, 2022

1 minute read

Piper Sandler analyst Charles Neivert maintains Olin (NYSE:OLN) with a Overweight and lowers the price target from $73 to $68.

Analyst Ratings

8 Analysts Have This to Say About CoStar Gr

By Benzinga Insights

April 26, 8:02 AM

Over the past 3 months, 8 analysts have published their opinion on CoStar Gr (NASDAQ:CSGP) stock. These analysts…

CSGP

Why Modular Medical Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket

By Lisa Levin

August 17, 8:15 AM

Gainers Modular Medical, Inc. (NASDAQ: MODD) shares surged 34.3% to $1.37 in pre-market trading after the company announced a partnership with Phillips-Medisize to expand insulin delivery alternatives.

AHI

Keybanc Maintains Overweight on Bumble, Raises Price Target to $28

By Benzinga Newsdesk

February 23, 4:59 AM

Keybanc analyst Justin Patterson maintains Bumble (NASDAQ:BMBL) with a Overweight and raises the price target from $27 to $28.

BMBL

Blueprint Medicines Announces Lift Of Partial Clinical Hold On Phase 1/2 VELA Trial Of BLU-222

By Happy Mohamed

March 28, 4:20 PM

Blueprint Medicines Corporation (NASDAQ:BPMC) today announced that the U.S. Food and Drug Administration (FDA) has lifted a partial clinical hold on the Phase 1/2 VELA trial of BLU-222. On February 10, 2023,

BPMC

Piper Sandler Maintains Overweight on Olin, Lowers Price Target to $68

Related Posts

8 Analysts Have This to Say About CoStar Gr

Why Modular Medical Shares Are Trading Higher By 34%; Here Are 20 Stocks Moving Premarket

Keybanc Maintains Overweight on Bumble, Raises Price Target to $28

Blueprint Medicines Announces Lift Of Partial Clinical Hold On Phase 1/2 VELA Trial Of BLU-222